It starts in the most familiar place imaginable: a doctor’s office. A patient in pain. A prescription that feels like relief. But behind that quiet moment was a pharmaceutical company running a million-dollar playbook.

Today's case dives into the rise and collapse of Insys Therapeutics, a drug company that built its empire around Subsys—a fentanyl spray approved for a narrow purpose: breakthrough cancer pain in opioid-tolerant patients.

What follows is a white-collar crime case with a body count hiding in the margins: doctors allegedly rewarded through “speaker programs,” prescriptions pushed far beyond cancer care, and an internal reimbursement operation that allegedly helped manipulate insurance approvals using scripts and misrepresentation—so Subsys could get paid for even when it shouldn’t have been approved.

How did Insys build an entire enterprise designed to turn medical decisions into revenue? This case reveals that in America, millions of deaths can hide behind the facade of white-collar crimes.